Medical/Pharmaceuticals
GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal
SEOUL, South Korea, March 30, 2021 /PRNewswire/ -- GemVax & KAEL Co., Ltd. (Korea: 082270)("GemVax") has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published onMarch 26 th in the SCI-grade international journal 'Alzheimer's Research & Ther...
2021-03-30 19:21
3988
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors
* Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chinese Patients with First Relapse of High-grade Astrocytoma * In-house discovered oral PD-L1 inhibitors demonstrated favorable anti-tumor activities in the animal model compared to a marketed anti-...
2021-03-30 08:00
4748
Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting
Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification PRINCETON, New Jersey, March 30, 2021 /PRNewswire/ -- During the 2021 Society of Toxicology (SOT) Annual Meeting, researchers from Swiss-based InSphero AG...
2021-03-30 05:20
1517
Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round
CINCINNATI, March 30, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...
2021-03-30 02:55
1779
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company
SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise...
2021-03-29 17:43
5806
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., March 29, 2021 /PRNewswire/ -- Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Task Team (AVATT) to make available up to 220 million dos...
2021-03-29 16:07
6080
HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....
2021-03-29 16:00
3370
Navigating China's Medical Technology, Regulations, Quality, and Future; Hundreds of Experts Gathered at On-site Conferences of Medtec China
SHANGHAI, March 29, 2021 /PRNewswire/ -- Medtec China 2021 will be held in Halls 2&4 of the Shanghai World Expo Exhibition Hall on September 1–3, and the "Innovation Technology Forum and Regulation Summit" will be held at the same time. This summit caters to the development trend and focus of Ch...
2021-03-29 09:30
3776
Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint
SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail t...
2021-03-29 08:27
5108
Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform
SHANGHAI, March 28, 2021 /PRNewswire/ -- Henlius (2696.HK) announced the financial results for the year ended31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation. The Company delivered a total r...
2021-03-28 11:16
3767
Genscript Biotech Reports Full Year 2020 Financial Results
Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...
2021-03-27 02:16
7430
Modern Chinese Medicine Announces Year 2020 Annual Results
Solid growth with focus to broaden the distribution network and raise R&D efforts PERFORMANCE HIGHLIGHTS * The Group posted a consolidated revenue of approximately RMB308.7 million for the year ended31 December 2020, representing an increase of approximately 41.1%. * For the year ended 31 D...
2021-03-26 22:08
12556
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years
BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years...
2021-03-26 21:31
4079
Artificial Joint Surgical Robot, CUVIS-joint developed by CUREXO Receives EEA CE Marking
* Expands partnership with European implant and medical enterprises * Pursues US FDA approval SEOUL, South Korea, March 26, 2021 /PRNewswire/ -- On the 25th, medical robot company CUREXO, Inc. (KOSDAQ: 060280) announced that the in-house developed artificial joint surgical robot CUVIS-joint re...
2021-03-26 17:00
3945
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, March 26, 2021 /PRNewswire/ --...
2021-03-26 16:00
3602
Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115
SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed publicati...
2021-03-26 08:38
3244
Antengene Announces Financial Results for Full Year 2020
SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" or "the company", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in h...
2021-03-26 08:00
4450
Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion
WUHAN, China, March 26, 2021 /PRNewswire/ -- Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment ofUS$190 million investment from institutional investors, and over $100 million investment has already been closed today. This round of fin...
2021-03-26 08:00
5939
Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round
CINCINNATI, March 26, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...
2021-03-26 05:19
3670
Antengene Appoints Kevin Lynch as Chief Medical Officer
SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in ...
2021-03-25 23:26
4571
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 322 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 290 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09